About this trial

The Abbott Structural Heart (SH) Registry is being conducted to confirm the safety and performance of Abbott's SH devices in a post-market, real-world setting. The Registry primarily involves gathering data from routine hospital practices and standard-of-care (SOC) procedures administered to patients. All devices used in these procedures must be commercially available to the participating site. A list of specific devices covered by the Registry are available upon request from the Sponsor. Data generated by the Registry will be used to meet regulatory requirements, such as the European Union Medical Device Regulations 2017/745, that require active post-market clinical follow-up (PMCF) for all commercially available devices.

Eligibility criteria

Qualifiers

Subject is expected to undergo an implant attempt using one or more Abbott Structural Heart devices covered in this Registry or has previously undergone an implant attempt within the timeframes specified in the device-specific appendices.

Subject is willing and able to comply with the site's standard of care follow-up schedule.

Subject is willing to provide appropriate informed consent for Registry participation. For deceased subjects enrolled retrospectively, local regulations and EC/IRB recommendations regarding consent and the protection of personal data must be followed.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Amplatzer™ Occlusion Devices
  • Epic™ Surgical Tissue Heart Valve devices

Treatment groups

2,500 Participants
are divided into 2 treatment groups

Locations

28
Denmark
Odense University Hospital5000, OdenseSouthern Denmark, Denmark
Estonia
Tartu University Hospital50406, TartuTartu, Estonia
France
CHRU Hopital de Pontchaillou35033, RennesBrittan, France
Centre Médico Chirurgical Marie Lannelongue92350, Le Plessis-Robinson France

Sponsors and collaborators

Abbott Medical Devices

Lead sponsor